New drug cocktail aims to tackle recurrent head and neck cancer

NCT ID NCT07059221

Recruiting now Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Jul 21, 2026 · Updated 3 times

Summary

This study tests a combination of two investigational drugs, SHR-A2102 and adebrelimab, with or without other anti-cancer therapies, in people whose head and neck squamous cell carcinoma has returned or spread. The goal is to find safe and effective doses and see if the combination can shrink tumors. Participants must have measurable disease and be in generally good health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR-A2102 and adebrelimab (with or without cetuximab, SHR-9839, or carboplatin/cisplatin)
What this could lead to: If successful, this combination could offer a new treatment option for people with head and neck cancer that has returned or spread.
What could go wrong: This is an early-phase trial (Phase 1/2) with a small number of participants, so the benefits and risks are not yet fully known. Side effects from the drug combinations may be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma Squamous Cell Carcinoma of Head and Neck

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Contacts and locations

Locations

Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.